loading...| Preferred Name | Tofacitinib Citrate | |
| Synonyms |
Tofacitinib Citrate CP-690,550-10 1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-Pyrrolo(2,3-d)Pyrimidin-4-ylamino)-Beta-Oxo-, (3R,4R)-, 2-Hydroxy-1,2,3-Propanetricarboxylate (1:1) Tasocitinib Citrate TOFACITINIB CITRATE Xeljanz |
|
| Definitions |
The citrate salt form of tofacitinib, an orally bioavailable inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon oral administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha (IFN-a) and -beta (IFN-b), and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C95801 |
|
| CAS_Registry |
540737-29-9 |
|
| Chemical_Formula |
C16H20N6O.C6H8O7 |
|
| code |
C95801 |
|
| Concept_In_Subset | ||
| Contributing_Source |
FDA |
|
| DEFINITION |
The citrate salt form of tofacitinib, an orally bioavailable inhibitor of Janus kinases (JAK), with immunomodulatory and anti-inflammatory activities. Upon oral administration, tofacitinib binds to JAK and prevents the activation of the JAK-signal transducers and activators of transcription (STAT) signaling pathway. This may decrease the production of pro-inflammatory cytokines, such as interleukin (IL)-6, -7, -15, -21, interferon-alpha (IFN-a) and -beta (IFN-b), and may prevent both an inflammatory response and the inflammation-induced damage caused by certain immunological diseases. JAK kinases are intracellular enzymes involved in signaling pathways affecting hematopoiesis, immunity and inflammation. |
|
| FDA_UNII_Code |
O1FF4DIV0D |
|
| FULL_SYN |
Tofacitinib Citrate CP-690,550-10 1-Piperidinepropanenitrile, 4-Methyl-3-(Methyl-7H-Pyrrolo(2,3-d)Pyrimidin-4-ylamino)-Beta-Oxo-, (3R,4R)-, 2-Hydroxy-1,2,3-Propanetricarboxylate (1:1) Tasocitinib Citrate TOFACITINIB CITRATE Xeljanz |
|
| Has_Free_Acid_Or_Base_Form | ||
| label |
Tofacitinib Citrate |
|
| Preferred_Name |
Tofacitinib Citrate |
|
| prefixIRI |
Thesaurus:C95801 |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C2715644 |
|
| subClassOf |